These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29048134)

  • 61. Pyoderma gangrenosum due to lenalidomide use for multiple myeloma.
    Dasanu CA; Bockorny B; Alexandrescu DT
    J Oncol Pharm Pract; 2015 Dec; 21(6):471-3. PubMed ID: 24986794
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [New indications for thalidomide?].
    Tuinmann G; Hegewisch-Becker S; Hossfeld DK
    Dtsch Med Wochenschr; 2001 Oct; 126(42):1178-82. PubMed ID: 11607859
    [No Abstract]   [Full Text] [Related]  

  • 63. Sporadic late-onset nemaline myopathy in a woman with multiple myeloma successfully treated with lenalidomide/dexamethasone.
    Montagnese F; Portaro S; Musumeci O; Migliorato A; Moggio M; Fagiolari G; Rodolico C
    Muscle Nerve; 2015 Jun; 51(6):934-5. PubMed ID: 25524603
    [No Abstract]   [Full Text] [Related]  

  • 64. An overview of the progress in the treatment of multiple myeloma.
    Kyle RA; Rajkumar SV
    Expert Rev Hematol; 2014 Feb; 7(1):5-7. PubMed ID: 24433105
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Necrobiotic xanthogranuloma associated with immunoglobulin m paraproteinemia in a patient with Waldenström macroglobulinemia.
    Balagula Y; Straus DJ; Pulitzer MP; Lacouture ME
    J Clin Oncol; 2011 Apr; 29(11):e305-7. PubMed ID: 21245419
    [No Abstract]   [Full Text] [Related]  

  • 66. Systemic therapy of necrobiotic xanthogranuloma: a systematic review.
    Steinhelfer L; Kühnel T; Jägle H; Mayer S; Karrer S; Haubner F; Schreml S
    Orphanet J Rare Dis; 2022 Mar; 17(1):132. PubMed ID: 35331271
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Necrobiotic xanthogranuloma of the extremities with paraproteinemia and without periorbital involvement at presentation.
    Hashemi P; Rashidi A; Chapas AM; Balfour EM
    Cutis; 2012 Jan; 89(1):41-4. PubMed ID: 22439311
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.
    Bennett CL; Angelotta C; Yarnold PR; Evens AM; Zonder JA; Raisch DW; Richardson P
    JAMA; 2006 Dec; 296(21):2558-60. PubMed ID: 17148721
    [No Abstract]   [Full Text] [Related]  

  • 69. Treatment of refractory necrobiotic xanthogranulomas with extracorporeal photopheresis and intravenous immunoglobulin.
    Liszewski W; Wisniewski JD; Safah H; Boh EE
    Dermatol Ther; 2014; 27(5):268-71. PubMed ID: 24910296
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Thalidomide and lenalidomide in primary myelofibrosis.
    Holle N; de Witte T; Mandigers C; Schaap N; Raymakers R
    Neth J Med; 2010 Aug; 68(1):293-8. PubMed ID: 20739725
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Haematological and molecular responses in refractory anaemia with ring sideroblasts and thrombocytosis treated with lenalidomide.
    Caers J; Hafraoui K; Keutgens A; Caberg JH; Lambert F; Tassin F; Beguin Y
    Eur J Haematol; 2014 Feb; 92(2):179-80. PubMed ID: 24299333
    [No Abstract]   [Full Text] [Related]  

  • 72. Necrobiotic xanthogranuloma.
    Efebera Y
    Clin Adv Hematol Oncol; 2011 Sep; 9(9):700-1. PubMed ID: 22402516
    [No Abstract]   [Full Text] [Related]  

  • 73. Transfer factor for the treatment of necrobiotic xanthogranuloma.
    Tang Z; Ruan J; Cai S
    Dermatol Ther; 2022 Dec; 35(12):e15894. PubMed ID: 36196500
    [No Abstract]   [Full Text] [Related]  

  • 74. Posterior Scleritis and Necrobiotic Xanthogranuloma.
    Ali FR; Young HS
    Ocul Immunol Inflamm; 2016; 24(1):91-2. PubMed ID: 26717063
    [No Abstract]   [Full Text] [Related]  

  • 75. Lenalidomide in myelodysplastic syndromes.
    List AF
    Clin Adv Hematol Oncol; 2008 Apr; 6(4):271-2, 311. PubMed ID: 18496493
    [No Abstract]   [Full Text] [Related]  

  • 76. Periocular Necrobiotic Xanthogranuloma Response to Cladribine.
    Agrawal S; Pushker N; Modaboyina S; Das D
    Ophthalmic Plast Reconstr Surg; 2022 Mar-Apr 01; 38(2):e64. PubMed ID: 34314397
    [No Abstract]   [Full Text] [Related]  

  • 77. Eosinophilia secondary to lenalidomide therapy.
    Escudero-Vilaplana V; Osorio-Prendes S; Collado-Borrell R; González-Arias E; Sanjurjo-Sáez M
    J Clin Pharm Ther; 2018 Apr; 43(2):273-275. PubMed ID: 28833364
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Image Gallery: Necrobiotic xanthogranuloma in association with chronic myelomonocytic leukaemia.
    Edwards LR; Kidd LL; Gru AA; Wilson BB
    Br J Dermatol; 2017 Feb; 176(2):e16. PubMed ID: 28244100
    [No Abstract]   [Full Text] [Related]  

  • 79. Lenalidomide to control gastrointestinal bleeding in hereditary haemorrhagic telangiectasia: potential implications for angiodysplasias?
    Bowcock SJ; Patrick HE
    Br J Haematol; 2009 Jul; 146(2):220-2. PubMed ID: 19438503
    [No Abstract]   [Full Text] [Related]  

  • 80. Single agent lenalidomide induces a response in refractory T-cell posttransplantation lymphoproliferative disorder.
    Portell C; Nand S
    Blood; 2008 Apr; 111(8):4416-7. PubMed ID: 18398059
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.